Talal Baki, MD
Interventional Cardiology · Rock Hill, SCNPI 1023093309
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for interventional cardiology clinicians in SC, where the typical reported total is $8,877.
Across 175 payments — averaging $41.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$972
- Actelion Pharmaceuticals US, Inc.$571
- Bayer$526
- Abiomed$435
- Boston Scientific$434
- Abbott$403
- plus $4K from 31 others
Across 64 payments — averaging $250.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotronik Inc.$16K
What the payments were for
- Food & beverage$7,14397%
- Education$1983%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 15 | $972 |
| Actelion Pharmaceuticals US, Inc. | 5 | $571 |
| Bayer | 8 | $526 |
| Abiomed | 5 | $435 |
| Boston Scientific | 6 | $434 |
| Abbott | 7 | $403 |
| AstraZeneca | 8 | $387 |
| Novartis | 18 | $355 |
| Johnson & Johnson | 18 | $345 |
| Merck | 12 | $294 |
| E.r. Squibb & Sons, L.L.C. | 16 | $276 |
| Novo Nordisk | 4 | $223 |
| Boehringer Ingelheim | 3 | $154 |
| Scpharmaceuticals Inc. | 2 | $153 |
| Teleflex LLC | 1 | $148 |
| Penumbra, Inc. | 1 | $143 |
| Edwards Lifesciences | 3 | $140 |
| Shockwave Medical, Inc | 1 | $139 |
| Biotronik Inc. | 2 | $130 |
| Kestra Medical Technology Services, Inc. | 5 | $124 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $123 |
| Inari Medical, Inc. | 1 | $117 |
| Heartflow, Inc. | 1 | $111 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $95 |
| Pfizer | 5 | $83 |
| Tactile Systems Technology Inc | 3 | $77 |
| Sanofi-aventis U.S. LLC | 4 | $71 |
| Amarin Pharma, Inc. | 4 | $60 |
| Lexicon Pharmaceuticals, Inc. | 3 | $47 |
| Amgen | 3 | $46 |
| Cvrx, Inc. | 2 | $39 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Atricure, Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Cleerly, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$532
- Impella$384
- UPTRAVI$366
- OPSUMIT$366
- Kerendia$362
- XARELTO$223
- VERQUVO$201
- WATCHMAN FLX$164
- Inspire Upper Airway Stimulation System$156
- GUIDELINER$148
- Indigo System$143
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$139
- AVVIGO Guidance System$130
- FUROSCIX$125
- ARCALYST$123
- Ozempic$121
- CardioMEMS HF System$120
- FLOWTRIEVER CATHETER, S$117
- CT THROMBECTOMY SYSTEM KIT$117
- FARXIGA$113
How this compares
$7,341 in reported general payments places this provider in the 40th percentile of 117 interventional cardiology providers in South Carolina.
See all interventional cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 232 | $278,276 |
| XareltoRivaroxaban | 48 | $45,595 |
| EntrestoSacubitril/Valsartan | 34 | $40,640 |
| BrilintaTicagrelor | 46 | $30,105 |
| FarxigaDapagliflozin Propanediol | 20 | $19,570 |
| Ranolazine ErRanolazine | 34 | $5,047 |
| Rosuvastatin Calcium | 247 | $4,929 |
| Warfarin Sodium | 391 | $3,625 |
| Metoprolol Succinate | 156 | $2,480 |
| Atorvastatin Calcium | 208 | $1,993 |
| Amlodipine Besylate | 293 | $1,958 |
| Carvedilol | 185 | $1,457 |
| ClopidogrelClopidogrel Bisulfate | 123 | $1,298 |
| Metoprolol Tartrate | 226 | $1,113 |
| Losartan Potassium | 119 | $1,098 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $83 | $278,276232 claims |
| AstraZenecaBrilinta, Farxiga | $387 | $49,67566 claims |
| Johnson & JohnsonXarelto | $345 | $45,59548 claims |
| NovartisEntresto | $355 | $40,64034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 117 interventional cardiology providers in South Carolina.
Other interventional cardiology in Rock Hill
- Rohit BhandariRock Hill$15K
- Jonathan EliasRock Hill$9K
- Daniel SteinbergCharleston$611K
- Brian BrownSpartanburg$389K
- Nicholas AmorosoPawleys Island$283K
- Robert LeonardiWest Columbia$203K
- Anbukarasi MaranCharleston$132K
- Jesse JorgensenGreenville$102K
- Thomas TodoranPawleys Island$95K
- Michael CryerColumbia$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.